Sam – Page 173 – biolegacy

Armed With New Patent, Indivior Sues Suboxone Generics Applicants

Post author:Sam
Post published:February 12, 2018
Post category:Drug Industry Daily

Indivior sued five competitors for infringing on its patent for the Suboxone sublingual film for treatment of opioid dependence. Source: Drug Industry Daily

FDA: PMRS Oxycodone NDA Did Not Include Enough Data on Abuse-Deterrent Properties

Post author:Sam
Post published:February 12, 2018
Post category:Drug Industry Daily

The FDA declined to approve a Pharmaceutical Manufacturing Research Services NDA for a new oxycodone hydrochloride product due to insufficient evidence of its abuse-deterrent properties, the agency said a Feb.…

Purdue Ends Opioid Marketing to Doctors

Post author:Sam
Post published:February 12, 2018
Post category:Drug Industry Daily

Purdue Pharmaceuticals announced that it will no longer promote its opioid products to doctors and will cut its sales force by more than half. Source: Drug Industry Daily

Amicus Investors Cheer as the FDA Shaves Four Months Off Its Fabry Drug Review Date

Post author:Sam
Post published:February 11, 2018
Post category:BioPharma

Amicus announced that the FDA accepted its NDA for migalastat to treat Fabry disease in patients with amenable mutations. Source: BioSpace

Biotech Startup Rubius to Double Footprint With New Kendall Square Lease

Post author:Sam
Post published:February 11, 2018
Post category:BioPharma

The fast-growing company will anchor 399 Binney St., an Alexandria Real Estate Equities property. Source: BioSpace

Cambridge's Surface Oncology Promotes CBO to Top Job

Post author:Sam
Post published:February 11, 2018
Post category:BioPharma

Mr. Goater succeeds interim chief executive officer Dan Lynch, who will remain executive chairman of Surface’s board of directors. Source: BioSpace

Sarepta Plunged After Adverse Event Forces Trial Halt in the UK

Post author:Sam
Post published:February 11, 2018
Post category:BioPharma

But the biotech swiftly indicated that it doesn’t expect the halt to last for long. Source: BioSpace

3 Drugs That Could Make-or-Break AbbVie

Post author:Sam
Post published:February 11, 2018
Post category:BioPharma

A look at three drug approvals of vital importance to the company this year. Source: BioSpace

Axovant CEO David Hung Abruptly Exits, COO and Several Directors Also Resign

Post author:Sam
Post published:February 11, 2018
Post category:BioPharma

Axovant shares plunged after Hung abruptly resigned as CEO and also stepped down from his seat on the company board of directors. Source: BioSpace

Genentech Shows Off New Mid-Stage DME Data

Post author:Sam
Post published:February 11, 2018
Post category:BioPharma

The study assessed two doses of RG7716 versus ranibizumab standard of care given as monthly intravitreal injections. Source: BioSpace